{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SPN-812",
    "query": {
      "intervention": "SPN-812"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 12,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SPN-812&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-02T06:04:10.662Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03247556",
      "title": "Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Adolescents With ADHD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "ADHD"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "400mg SPN-812",
          "type": "DRUG"
        },
        {
          "name": "600mg SPN-812",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Supernus Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 297,
      "start_date": "2017-11-20",
      "completion_date": "2019-02-14",
      "has_results": true,
      "last_update_posted_date": "2021-07-02",
      "last_synced_at": "2026-09-02T06:04:10.662Z",
      "location_count": 14,
      "location_summary": "Long Beach, California • Colorado Springs, Colorado • Bradenton, Florida + 9 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        },
        {
          "city": "Lauderhill",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03247556"
    },
    {
      "nct_id": "NCT04781140",
      "title": "Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Attention-Deficit/Hyperactivity Disorder"
      ],
      "interventions": [
        {
          "name": "100mg SPN-812",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Supernus Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "48 Months",
        "maximum_age": "69 Months",
        "sex": "ALL",
        "summary": "48 Months to 69 Months"
      },
      "enrollment_count": 286,
      "start_date": "2024-03-19",
      "completion_date": "2026-06",
      "has_results": false,
      "last_update_posted_date": "2026-02-18",
      "last_synced_at": "2026-09-02T06:04:10.662Z",
      "location_count": 47,
      "location_summary": "Saraland, Alabama • Little Rock, Arkansas • Anaheim, California + 41 more",
      "locations": [
        {
          "city": "Saraland",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Imperial",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04781140"
    },
    {
      "nct_id": "NCT04143217",
      "title": "Open-label Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Attention-Deficit/Hyperactivity Disorder"
      ],
      "interventions": [
        {
          "name": "SPN-812",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Supernus Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 159,
      "start_date": "2020-01-23",
      "completion_date": "2022-12-14",
      "has_results": true,
      "last_update_posted_date": "2024-02-13",
      "last_synced_at": "2026-09-02T06:04:10.662Z",
      "location_count": 38,
      "location_summary": "Beverly Hills, California • Garden Grove, California • Los Alamitos, California + 33 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04143217"
    },
    {
      "nct_id": "NCT04786990",
      "title": "Open-Label Study of SPN-812 Administered With Psychostimulants in Children and Adolescents With ADHD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Attention-Deficit/Hyperactivity Disorder (ADHD)"
      ],
      "interventions": [
        {
          "name": "SPN-812",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Supernus Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 96,
      "start_date": "2021-07-27",
      "completion_date": "2023-07-26",
      "has_results": true,
      "last_update_posted_date": "2024-05-01",
      "last_synced_at": "2026-09-02T06:04:10.662Z",
      "location_count": 16,
      "location_summary": "Little Rock, Arkansas • Orange, California • Miami, Florida + 13 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Blackfoot",
          "state": "Idaho"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04786990"
    },
    {
      "nct_id": "NCT03247517",
      "title": "Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Adolescents With ADHD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "ADHD"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "200mg SPN-812",
          "type": "DRUG"
        },
        {
          "name": "400mg SPN-812",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Supernus Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 310,
      "start_date": "2017-11-02",
      "completion_date": "2018-10-17",
      "has_results": true,
      "last_update_posted_date": "2021-06-18",
      "last_synced_at": "2026-09-02T06:04:10.662Z",
      "location_count": 12,
      "location_summary": "Dothan, Alabama • Orange, California • Hialeah, Florida + 9 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03247517"
    },
    {
      "nct_id": "NCT06259331",
      "title": "Evaluation of Viloxazine and Its Metabolite 5-Hydroxy-viloxazine Glucuronide Into Breast Milk in Healthy Lactating Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Healthy Lactating Women"
      ],
      "interventions": [
        {
          "name": "SPN-812 (600mg, QD)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Supernus Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 15,
      "start_date": "2023-05-23",
      "completion_date": "2023-09-20",
      "has_results": true,
      "last_update_posted_date": "2024-06-06",
      "last_synced_at": "2026-09-02T06:04:10.662Z",
      "location_count": 1,
      "location_summary": "Las Vegas, Nevada",
      "locations": [
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06259331"
    },
    {
      "nct_id": "NCT03247543",
      "title": "Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Children With ADHD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "ADHD"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "200mg SPN-812",
          "type": "DRUG"
        },
        {
          "name": "400mg SPN-812",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Supernus Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "6 Years to 11 Years"
      },
      "enrollment_count": 313,
      "start_date": "2017-10-31",
      "completion_date": "2018-10-17",
      "has_results": true,
      "last_update_posted_date": "2021-07-08",
      "last_synced_at": "2026-09-02T06:04:10.662Z",
      "location_count": 10,
      "location_summary": "Long Beach, California • Lauderhill, Florida • Orlando, Florida + 7 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Lauderhill",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03247543"
    },
    {
      "nct_id": "NCT04016779",
      "title": "Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Attention-Deficit/Hyperactivity Disorder (ADHD)"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "SPN-812",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Supernus Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 374,
      "start_date": "2019-11-20",
      "completion_date": "2020-10-10",
      "has_results": true,
      "last_update_posted_date": "2022-07-12",
      "last_synced_at": "2026-09-02T06:04:10.662Z",
      "location_count": 37,
      "location_summary": "Garden Grove, California • Los Alamitos, California • Newport Beach, California + 32 more",
      "locations": [
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04016779"
    },
    {
      "nct_id": "NCT02633527",
      "title": "Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Attention-Deficit/Hyperactivity Disorder (ADHD)"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "100mg SPN-812",
          "type": "DRUG"
        },
        {
          "name": "200mg SPN-812",
          "type": "DRUG"
        },
        {
          "name": "300mg SPN-812",
          "type": "DRUG"
        },
        {
          "name": "400mg SPN-812",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Supernus Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "6 Years to 12 Years"
      },
      "enrollment_count": 222,
      "start_date": "2016-02-01",
      "completion_date": "2016-07-25",
      "has_results": true,
      "last_update_posted_date": "2021-10-27",
      "last_synced_at": "2026-09-02T06:04:10.662Z",
      "location_count": 1,
      "location_summary": "Maitland, Florida",
      "locations": [
        {
          "city": "Maitland",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02633527"
    },
    {
      "nct_id": "NCT03247530",
      "title": "Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Children With ADHD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "ADHD"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "100mg SPN-812",
          "type": "DRUG"
        },
        {
          "name": "200mg SPN-812",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Supernus Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "6 Years to 11 Years"
      },
      "enrollment_count": 477,
      "start_date": "2017-10-20",
      "completion_date": "2018-09-12",
      "has_results": true,
      "last_update_posted_date": "2021-07-02",
      "last_synced_at": "2026-09-02T06:04:10.662Z",
      "location_count": 7,
      "location_summary": "Dothan, Alabama • Hialeah, Florida • Meridian, Idaho + 4 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Meridian",
          "state": "Idaho"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03247530"
    }
  ]
}